Full video transcriptClick to expand
Auto-generated transcript of @drmelindasilvamd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00How is it taken?
- 0:01It's given typically as a subcutaneous injection
- 0:04so right under the skin, at least 45 minutes
- 0:07to an hour before intimacy, but some patients say
- 0:10it may take two, four, six, eight, one patient
- 0:14even said 12 hours before it worked.
- 0:16So plan accordingly.
- 0:18Women with hyposexual, desired disorder,
- 0:21men or women who feel disconnected from intimacy,
- 0:25and anyone wanting to rekindle the recentiality
- 0:28and feel in touch with their body again,
- 0:30let's stop whispering about lollopetto
- 0:33and start treating it with science, compassion and results.
Does PT-141 actually rekindle libido, or is it hype?
Quick answer
Bremelanotide (PT-141) is FDA-approved as Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women, with Phase 3 trial data supporting its melanocortin receptor mechanism. Its use in men or postmenopausal women remains off-label with limited clinical evidence. Compounded PT-141 peptide products are not equivalent to the approved drug and carry uncharacterized safety profiles.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
PT-141 (Bremelanotide) access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does PT-141 actually rekindle libido, or is it hype?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
SCENESSE (afamelanotide implant) FDA Prescribing Information
Afamelanotide (an alpha-MSH analog) is the only FDA-approved melanocortin peptide of this class, and only to increase pain-free light exposure in erythropoietic protoporphyria, not for cosmetic tanning.
FDA
Afamelanotide for Erythropoietic Protoporphyria
Randomized placebo-controlled trials (NEJM) behind the afamelanotide approval; this is the legitimate human melanocortin evidence, distinct from unapproved tanning peptides.
PubMed
VYLEESI (bremelanotide injection) FDA Prescribing Information
Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approval is limited to that indication.
FDA
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Pivotal RECONNECT studies: two double-blind placebo-controlled Phase 3 trials (1,267 women) showing improved sexual desire and reduced distress versus placebo.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
PT-141 (Bremelanotide) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Does PT-141 actually rekindle libido, or is it hype?" from Dr. Melinda Silva MD. We read the clip as a Peptide social video fact-checks claim about PT-141 (Bremelanotide), then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Bremelanotide (PT-141) is FDA-approved as Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women, with Phase 3 trial data supporting its melanocortin receptor mechanism.
The reason this review is not generic is the source wording and the canonical claim label "peptides this peptide could rekindle your s3x drive hormone libido we." In this clip, the useful excerpt is: "How is it taken?" That wording changes the review because it points to PT-141 (Bremelanotide) safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against SCENESSE (afamelanotide implant) FDA Prescribing Information (2019), Afamelanotide for Erythropoietic Protoporphyria (2015), and Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (2012), plus the creator's own wording. PT-141 (Bremelanotide) still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Bremelanotide (PT-141) is FDA-approved as Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women, with Phase 3 trial data supporting its melanocortin receptor mechanism.
FormBlends verdict
PT-141 (Bremelanotide) safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the PT-141 (Bremelanotide) guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Bremelanotide (PT-141) is FDA-approved as Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women, with Phase 3 trial data supporting its melanocortin receptor mechanism. Its use in men or postmenopausal women remains off-label with limited clinical evidence. Compounded PT-141 peptide products are not equivalent to the approved drug and carry uncharacterized safety profiles.
- Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women only, based on two Phase 3 trials published in 2016 and 2019.
- Roughly 40 percent of participants in the Kingsberg et al. 2019 trial reported nausea, the most common adverse event. This was not mentioned in the video.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- PT-141 (Bremelanotide) decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the PT-141 (Bremelanotide) guide, cost path, safety notes, and provider review before acting.
Review PT-141 (Bremelanotide)What You'll Learn
- Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women only, based on two Phase 3 trials published in 2016 and 2019.
- Roughly 40 percent of participants in the Kingsberg et al. 2019 trial reported nausea, the most common adverse event. This was not mentioned in the video.
- There is no FDA-approved indication for PT-141 in men. The one published male trial (Safarinejad, 2008) is insufficient to support a general libido claim.
- Compounded PT-141 peptide products available through telehealth or peptide vendors are not equivalent to FDA-approved Vyleesi and have not undergone the same safety or efficacy evaluation.
- The wide onset window described (45 minutes to 12 hours) reflects real variability, but the 12-hour figure falls well outside the studied pharmacokinetic range and warrants physician discussion, not casual planning advice.
- Low libido in men often has identifiable treatable causes including low testosterone, cardiovascular issues, or depression. PT-141 does not address those root causes.
- Transient increases in blood pressure have been documented with bremelanotide use, making it potentially unsuitable for people with hypertension or cardiovascular risk factors.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drmelindasilvamd actually say?
The video promotes a peptide, referred to as "lollopetto" in the transcript (almost certainly a transcription error for PT-141, also known as bremelanotide), as a treatment for low libido in men and women. She describes it as a subcutaneous injection taken anywhere from 45 minutes to 12 hours before sexual activity. She names specific patient populations: women with "hyposexual desired disorder" (likely hypoactive sexual desire disorder, or HSDD), people who feel "disconnected from intimacy," and anyone wanting to "rekindle" desire. The call to action is to treat low libido "with science, compassion and results."
To her credit, she stays away from miracle language. She does not claim PT-141 will work for everyone, and she acknowledges the wide variability in onset time, which is actually consistent with real-world clinical reports. That said, she leaves out a lot of information that viewers would need to make any sense of this.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Melinda Silva MD · TikTok creator
11.4K views on this video
This Peptide Could Rekindle Your S3x Drive #hormone #libido #wellness #wellnesshackermd #womenshealth #menshealth #doctor #viral #doctorsoftiktok #part2?
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about bremelanotide (vyleesi)?
Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women only, based on two Phase 3 trials published in 2016 and 2019.
What does the video say about roughly 40 percent of participants in the kingsberg et al.?
Roughly 40 percent of participants in the Kingsberg et al. 2019 trial reported nausea, the most common adverse event. This was not mentioned in the video.
What does the video say about there?
There is no FDA-approved indication for PT-141 in men. The one published male trial (Safarinejad, 2008) is insufficient to support a general libido claim.
What does the video say about compounded pt-141 peptide products available through telehealth?
Compounded PT-141 peptide products available through telehealth or peptide vendors are not equivalent to FDA-approved Vyleesi and have not undergone the same safety or efficacy evaluation.
What does the video say about the wide onset window described (45 minutes to 12 hours)?
The wide onset window described (45 minutes to 12 hours) reflects real variability, but the 12-hour figure falls well outside the studied pharmacokinetic range and warrants physician discussion, not casual planning advice.
What does the video say about low libido in men often has identifiable treatable causes including?
Low libido in men often has identifiable treatable causes including low testosterone, cardiovascular issues, or depression. PT-141 does not address those root causes.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Melinda Silva MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.